Patents by Inventor Catherine Jorand-Lebrun

Catherine Jorand-Lebrun has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted pyrazoles as type II IRAK inhibitors
    Patent number: 11873303
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: January 16, 2024
    Assignee: Merck Patent GmbH
    Inventors: Catherine Jorand-Lebrun, Nadia Brugger, Theresa Johnson
  • ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF
    Publication number: 20230321052
    Abstract: The invention provides ?-amino esters of a hydroxypropylthiazolidine carboxamide derivative, (2S)-3-([1,1?-biphenyl]-4-ylsulfonyl)-N-[(1S)-3-hydroxy-1-phenylpropyl]-1,3-thiazolidine-2-carboxamide, as well as salts and crystal polymorphs thereof, that can be used to inhibit prostaglandin F receptor. The invention further encompasses methods of treating disorders such as preterm labor at the early gestational stage by the administration of these substances to a patient in need of treatment.
    Type: Application
    Filed: November 10, 2022
    Publication date: October 12, 2023
    Inventors: Patrick Naxos PAGE, Matthias SCHWARZ, Catherine JORAND-LEBRUN, Anna QUATTROPANI, Vincent POMEL, Ernest LOUMAYE, Oliver POHL, Jean-Pierre GOTTELAND
  • Pyrimidinone derivatives as SHP2 antagonists
    Patent number: 11702392
    Abstract: The invention relates to pyrimidinone derivatives of the general Formula I, or a pharmaceutically acceptable salt thereof, and the use of the compounds of the present invention for the treatment of hyperproliferative diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.
    Type: Grant
    Filed: February 22, 2021
    Date of Patent: July 18, 2023
    Assignee: Merck Patent GmbH
    Inventors: Catherine Jorand-Lebrun, Roch Boivin, Theresa Johnson, Yanping Wang, Yufang Xiao, Xiaoling Chen, Nina Linde, Doreen Musch, Deepak Kumar
  • Carboxamide-pyrimidine derivatives as SHP2 antagonists
    Patent number: 11696916
    Abstract: The invention relates to carboxamide-pyrimidine derivatives of the general formula I, or a pharmaceutically acceptable salt thereof, and the use of the compounds of the present invention for the treatment of hyperproliferative diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.
    Type: Grant
    Filed: April 30, 2021
    Date of Patent: July 11, 2023
    Assignee: Merck Patent GmbH
    Inventors: Catherine Jorand-Lebrun, Roch Boivin, Igor Mochalkin, Theresa Johnson, Nina Linde, Doreen Musch, Deepak Kumar
  • Quinoline compounds as IRAK inhibitors and uses thereof
    Patent number: 11542246
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: January 3, 2023
    Assignee: Merck Patent GmbH
    Inventors: Catherine Jorand-Lebrun, Roch Boivin
  • Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
    Patent number: 11524003
    Abstract: The invention provides ?-amino esters of a hydroxypropylthiazolidine carboxamide derivative, (2S)-3-([1,1?-biphenyl]-4-ylsulfonyl)-N-[(1S)-3-hydroxy-1-phenylpropyl]-1,3-thiazolidine-2-carboxamide, as well as salts and crystal polymorphs thereof, that can be used to inhibit prostaglandin F receptor. The invention further encompasses methods of treating disorders such as preterm labor at the early gestational stage by the administration of these substances to a patient in need of treatment.
    Type: Grant
    Filed: January 27, 2020
    Date of Patent: December 13, 2022
    Assignee: ObsEva S.A.
    Inventors: Patrick Naxos Page, Matthias Schwarz, Catherine Jorand-Lebrun, Anna Quattropani, Vincent Pomel, Ernest Loumaye, Oliver Pohl, Jean-Pierre Gotteland
  • CARBOXAMIDE-PYRIMIDINE DERIVATIVES AS SHP2 ANTAGONISTS
    Publication number: 20220362244
    Abstract: The invention relates to carboxamide-pyrimidine derivatives of the general formula I, or a pharmaceutically acceptable salt thereof, and the use of the compounds of the present invention for the treatment of hyperproliferative diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.
    Type: Application
    Filed: April 30, 2021
    Publication date: November 17, 2022
    Inventors: Catherine JORAND-LEBRUN, Roch BOIVIN, Igor MOCHALKIN, Theresa JOHNSON, Nina LINDE, Doreen MUSCH, Deepak KUMAR
  • ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF
    Publication number: 20210323935
    Abstract: The invention provides ?-amino esters of a hydroxypropylthiazolidine carboxamide derivative, (2S)-3-([1,1?-biphenyl]-4-ylsulfonyl)-N-[(1S)-3-hydroxy-1-phenylpropyl]-1,3-thiazolidine-2-carboxamide, as well as salts and crystal polymorph s thereof, that can be used to inhibit prostaglandin F receptor. The invention further encompasses methods of treating disorders such as pre-term labor at the early gestational stage by the administration of these substances to a patient in need of treatment.
    Type: Application
    Filed: December 4, 2020
    Publication date: October 21, 2021
    Inventors: Patrick Naxos PAGE, Matthias SCHWARZ, Catherine JORAND-LEBRUN, Anna QUATTROPANI, Vincent POMEL
  • PYRIMIDINONE DERIVATIVES AS SHP2 ANTAGONISTS
    Publication number: 20210179565
    Abstract: The invention relates to pyrimidinone derivatives of the general Formula I, or a pharmaceutically acceptable salt thereof, and the use of the compounds of the present invention for the treatment of hyperproliferative diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.
    Type: Application
    Filed: February 22, 2021
    Publication date: June 17, 2021
    Inventors: Catherine JORAND-LEBRUN, Roch BOIVIN, Theresa JOHNSON, Yanping WANG, Yufang XIAO, Xiaoling CHEN, Nina LINDE, Doreen MUSCH, Deepak KUMAR
  • Carboxamide-pyrimidine derivatives as SHP2 antagonists
    Patent number: 11033547
    Abstract: The invention relates to carboxamide-pyrimidine derivatives of the general formula I, or a pharmaceutically acceptable salt thereof, and the use of the compounds of the present invention for the treatment of hyperproliferative diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.
    Type: Grant
    Filed: March 9, 2020
    Date of Patent: June 15, 2021
    Assignee: Merck Patent GmbH
    Inventors: Catherine Jorand-LeBrun, Roch Boivin, Igor Mochalkin, Theresa Johnson, Nina Linde, Doreen Musch, Deepak Kumar
  • HETEROARYL COMPOUNDS AS TYPE II IRAK INHIBITORS AND USES THEREOF
    Publication number: 20210163487
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.
    Type: Application
    Filed: April 1, 2019
    Publication date: June 3, 2021
    Inventors: Catherine JORAND-LEBRUN, Nadia BRUGGER, Theresa JOHNSON
  • Pyrimidinone derivatives as SHP2 antagonists
    Patent number: 11001561
    Abstract: The invention relates to pyrimidinone derivatives of the general Formula I, or a pharmaceutically acceptable salt thereof, and the use of the compounds of the present invention for the treatment of hyperproliferative diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: May 11, 2021
    Assignee: Merck Patent GmbH
    Inventors: Catherine Jorand-Lebrun, Roch Boivin, Theresa Johnson, Yanping Wang, Yufang Xiao, Xiaoling Chen, Nina Linde, Doreen Musch, Deepak Kumar
  • QUINOLINE COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF
    Publication number: 20200369646
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.
    Type: Application
    Filed: January 15, 2019
    Publication date: November 26, 2020
    Inventors: Catherine JORAND-LEBRUN, Roch BOIVIN
  • PYRIMIDINONE DERIVATIVES AS SHP2 ANTAGONISTS
    Publication number: 20200317622
    Abstract: The invention relates to pyrimidinone derivatives of the general Formula I, or a pharmaceutically acceptable salt thereof, and the use of the compounds of the present invention for the treatment of hyperproliferative diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.
    Type: Application
    Filed: April 8, 2020
    Publication date: October 8, 2020
    Inventors: Catherine Jorand-Lebrun, Roch Boivin, Theresa Johnson, Yanping Wang, Yufang Xiao, Xiaoling Chen, Nina Linde, Doreen Musch, Deepak Kumar
  • CARBOXAMIDE-PYRIMIDINE DERIVATIVES AS SHP2 ANTAGONISTS
    Publication number: 20200281926
    Abstract: The invention relates to carboxamide-pyrimidine derivatives of the general formula I, or a pharmaceutically acceptable salt thereof, and the use of the compounds of the present invention for the treatment of hyperproliferative diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.
    Type: Application
    Filed: March 9, 2020
    Publication date: September 10, 2020
    Inventors: Catherine JORAND-LEBRUN, Roch BOIVIN, Igor MOCHALKIN, Theresa JOHNSON, Nina LINDE, Doreen MUSCH, Deepak KUMAR
  • ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF
    Publication number: 20200155515
    Abstract: The invention provides ?-amino esters of a hydroxypropylthiazolidine carboxamide derivative, (2S)-3-([1,1?-biphenyl]-4-ylsulfonyl)-N-[(1S)-3-hydroxy-1-phenylpropyl]-1,3-thiazolidine-2-carboxamide, as well as salts and crystal polymorphs thereof, that can be used to inhibit prostaglandin F receptor. The invention further encompasses methods of treating disorders such as preterm labor at the early gestational stage by the administration of these substances to a patient in need of treatment.
    Type: Application
    Filed: January 27, 2020
    Publication date: May 21, 2020
    Inventors: Patrick Naxos PAGE, Matthias SCHWARZ, Catherine JORAND-LEBRUN, Anna QUATTROPANI, Vincent POMEL, Ernest LOUMAYE, Oliver POHL, Jean-Pierre GOTTELAND
  • Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
    Patent number: 10555934
    Abstract: The invention provides pharmaceutical compositions comprising a compound of formula (I) or (II) and an additional therapeutic agent Also provided is the HCI salt and crystalline form of the compound of formula (I). The compounds inhibit the prostaglandin F receptor (PGF2alpha) and thus useful in the treatment of disorders such as preterm labor at the early gestational stage.
    Type: Grant
    Filed: January 4, 2017
    Date of Patent: February 11, 2020
    Assignee: ObsEva S.A.
    Inventors: Patrick Naxos Page, Matthias Schwarz, Catherine Jorand-Lebrun, Anna Quattropani, Vincent Pomel, Ernest Loumaye, Oliver Pohl, Jean-Pierre Gotteland
  • Pyridazinone macrocycles as IRAK inhibitors and uses thereof
    Patent number: 10517872
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.
    Type: Grant
    Filed: March 6, 2017
    Date of Patent: December 31, 2019
    Assignee: Merck Patent GmbH
    Inventors: Xiaoling Chen, Ruoxi Lan, Catherine Jorand-Lebrun, Henry Yu, Andreas Goutopoulos
  • Heteroaryl compounds as IRAK inhibitors and uses thereof
    Patent number: 10392375
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: August 27, 2019
    Assignee: Merck Patent GmbH
    Inventors: Catherine Jorand-Lebrun, Ruoxi Lan, Austin Chen, Ryan C. Clark
  • ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF
    Publication number: 20190194151
    Abstract: The invention provides ?-amino esters of a hydroxypropylthiazolidine carboxamide derivative, (2S)-3-([1,1?-biphenyl]-4-ylsulfonyl)-N-[(1S)-3-hydroxy-1-phenylpropyl]-1,3-thiazolidine-2-carboxamide, as well as salts and crystal polymorph s thereof, that can be used to inhibit prostaglandin F receptor. The invention further encompasses methods of treating disorders such as pre-term labor at the early gestational stage by the administration of these substances to a patient in need of treatment.
    Type: Application
    Filed: February 28, 2019
    Publication date: June 27, 2019
    Inventors: Patrick Naxos PAGE, Matthias SCHWARZ, Catherine JORAND-LEBRUN, Anna QUATTROPANI, Vincent POMEL